Unnamed: 0,title,date,stock,sentiment
759613.0,Stocks That Hit 52-Week Highs On Friday,2020-06-05 10:30:00-04:00,LGND,neutral
759614.0,"Ligand Pharma Reports Icagen To Expand Collaboration With Roche To Develop, Commercialize Therapies For Neurological Diseases, Co. Could Receive Up To $274M In Milestone Payments",2020-05-29 08:11:00-04:00,LGND,positive
759615.0,Ligand Earns $3M Milestone Payment From Palvella Therapeutics,2020-05-28 16:22:00-04:00,LGND,neutral
759616.0,Biotech Stock Rally Is Crushing Short Sellers,2020-05-11 12:15:00-04:00,LGND,negative
759617.0,Ligand Pharmaceuticals shares are trading lower despite the company reporting better-than-expected Q1 EPS and sales results.,2020-05-06 16:13:00-04:00,LGND,neutral
759618.0,Ligand Sees FY20 Sales Of $140M And EPS $3.65,2020-05-06 16:07:00-04:00,LGND,neutral
759619.0,"Ligand Pharmaceuticals Q1 EPS $0.890 Beats $0.660 Estimate, Sales $33.200M Beat $26.530M Estimate",2020-05-06 16:06:00-04:00,LGND,neutral
759620.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,LGND,positive
759621.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,LGND,neutral
759622.0,10 Biggest Price Target Changes For Wednesday,2020-04-08 08:22:00-04:00,LGND,neutral
759623.0,"HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $229",2020-04-08 08:02:00-04:00,LGND,negative
759624.0,"Benzinga's Top Upgrades, Downgrades For March 24, 2020",2020-03-24 10:02:00-04:00,LGND,positive
759625.0,Argus Research Downgrades Ligand Pharmaceuticals to Hold,2020-03-24 08:36:00-04:00,LGND,neutral
759626.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,LGND,positive
759627.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,LGND,negative
759628.0,Guggenheim Securities Initiates Coverage On Ligand Pharmaceuticals with Neutral Rating,2020-03-10 04:56:00-04:00,LGND,positive
759629.0,100 Stocks Moving In Thursday's Mid-Day Session,2020-02-27 12:24:00-05:00,LGND,neutral
759630.0,"UPDATE: Ligand Pharma Raises FY20 EPS Guidance From $3.45 To $3.62 vs $3.47 Estimate, Sales From ~$128M To ~$133M vs $125.8M Est.",2020-02-27 08:01:00-05:00,LGND,neutral
759631.0,"Ligand Pharma Raises FY20 Guidance, Cites Higher Captisol Material Sales",2020-02-27 08:01:00-05:00,LGND,neutral
759632.0,Ligand Raises FY20 Adj. EPS Guidance From $3.40 To $3.45 vs $3.44 Estimate,2020-02-11 16:15:00-05:00,LGND,neutral
759633.0,"Ligand Pharma Reports Purchase Of Core Assets, Partnered Programs, Ion Channel Technologies From Icagen For $15M In Cash",2020-02-11 16:14:00-05:00,LGND,positive
759634.0,Ligand Pharmaceuticals Sees FY20 Sales Guidance Of $121M Vs 124.49M Estimate; EPS $3.40 Vs $3.49 Estimate,2020-02-06 16:03:00-05:00,LGND,neutral
759635.0,"Ligand Pharmaceuticals Q4 EPS $0.71 Beats $0.61 Estimate, Sales $27M Beat $25.16M Estimate",2020-02-06 16:01:00-05:00,LGND,neutral
759636.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2020",2020-02-06 09:35:00-05:00,LGND,positive
759637.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,LGND,negative
759638.0,Ligand Pharmaceuticals Says Its Technologies Are 'being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus',2020-02-03 08:34:00-05:00,LGND,positive
759639.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,LGND,neutral
759640.0,Ligand Enters Into OmniAb Platform License Agreement With Pandion Therapeutics,2020-01-13 16:03:00-05:00,LGND,positive
759641.0,25 Stocks Moving in Monday's Pre-Market Session,2020-01-13 07:30:00-05:00,LGND,neutral
759642.0,12 Biotech Stocks Primed For A Short Squeeze,2019-12-06 08:00:00-05:00,LGND,neutral
759643.0,Ligand Announces the Licensing of its OmbniAb to Sanofi,2019-12-02 08:32:00-05:00,LGND,neutral
759644.0,Ligand Presents Results From Phase 1 Clinical Trial Of Captisol-Enabled Iohexol At American Society Of Nephrology Kidney Week 2019,2019-11-08 08:31:00-05:00,LGND,neutral
759645.0,Ligand Pharmaceuticals Cuts FY19 Adj. EPS Guidance From $3.20 to $3.00 vs $3.25 Est.,2019-11-05 16:08:00-05:00,LGND,negative
759646.0,Ligand Reaffirms FY19 Sales Guidance $118M vs $119.71M Est.,2019-11-05 16:07:00-05:00,LGND,neutral
759647.0,"Ligand Pharmaceuticals Q3 EPS $0.49 Misses $0.61 Estimate, Sales $24.8M Beat $22.36M Estimate",2019-11-05 16:05:00-05:00,LGND,negative
759648.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,LGND,negative
759649.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,LGND,neutral
759650.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,LGND,positive
759651.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,LGND,neutral
759652.0,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",2019-10-20 08:08:00-04:00,LGND,positive
759653.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,LGND,neutral
759654.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,LGND,neutral
759655.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,LGND,negative
759656.0,Ligand Pharmaceuticals Licensee Sermonix Doses First Patient In Phase 2 Clinical Trial Of Lasofoxifene For Targeted Precision Medicine Treatment Of Women With ESR1 Mutations In Metastatic Breast Cancer,2019-09-23 10:02:00-04:00,LGND,negative
759657.0,"Benzinga's Top Upgrades, Downgrades For September 19, 2019",2019-09-19 10:21:00-04:00,LGND,positive
759658.0,10 Biggest Price Target Changes For Thursday,2019-09-19 08:34:00-04:00,LGND,neutral
759659.0,"Barclays Upgrades Ligand Pharmaceuticals to Overweight, Raises Price Target to $132",2019-09-19 06:25:00-04:00,LGND,negative
759660.0,Ligand Pharmaceuticals Says Recently Entered Into an Omniab Commercial Platform License Agreement With Hong Kong-based Kira Pharmaceuticals,2019-09-12 06:09:00-04:00,LGND,positive
759661.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,LGND,positive
759662.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,LGND,positive
759663.0,Ligand Pharma Reports Partnership With CASI Pharma To Launch EVOMELA in China,2019-08-12 09:00:00-04:00,LGND,neutral
759664.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,LGND,positive
759665.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,LGND,negative
759666.0,"Barclays Maintains Equal-Weight on Ligand Pharmaceuticals, Lowers Price Target to $110",2019-08-05 08:30:00-04:00,LGND,negative
759667.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,LGND,negative
759668.0,80 Biggest Movers From Yesterday,2019-07-31 05:28:00-04:00,LGND,neutral
759669.0,Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings,2019-07-30 13:32:00-04:00,LGND,positive
759670.0,58 Stocks Moving In Tuesday's Mid-Day Session,2019-07-30 12:39:00-04:00,LGND,neutral
759671.0,Ligand Pharmaceuticals: Lemelson Capital Management Announces That It Had Increased Its Short Position In Ligand Pharmaceuticals,2019-07-30 11:31:00-04:00,LGND,positive
759672.0,New 52-Week Lows for Tuesday Morning,2019-07-30 11:07:00-04:00,LGND,negative
759673.0,"Ligand Pharmaceuticals Q2 EPS $0.68 Beats $0.55 Estimate, Sales $24.99M Beat $21.01M Estimate",2019-07-30 08:02:00-04:00,LGND,neutral
759674.0,Ligand Pharma Reports Purchase Of Ab Initio Biotherapeutics For $12M In Cash,2019-07-23 16:40:00-04:00,LGND,neutral
759675.0,Ligand Announces Phase 1 Clinical Trial Of Captisol-enabled Iohexol Achieved Primary Endpoint,2019-07-10 09:02:00-04:00,LGND,neutral
759676.0,Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol License And Supply Agreements For High-Concentration Furosemide Formulation,2019-07-08 08:33:00-04:00,LGND,positive
759677.0,"Ligand Pharma Has Entered Into OmniAb Commercial Platform License, Services Deal With Takeda's Millennium",2019-07-03 06:22:00-04:00,LGND,neutral
759678.0,"Ligand Pharmaceuticals Highlights Launch Of Sage Therapeutics' ZULRESSO, Which Utilizes Ligand's Captisol",2019-07-01 09:12:00-04:00,LGND,neutral
759679.0,Ligand Pharma Reports Subsidiary Vernalis And PhoreMost Report Drug Discovery Collaboration For Novel Oncology Target,2019-06-12 09:06:00-04:00,LGND,positive
759680.0,"Barclays Initiates Coverage On Ligand Pharmaceuticals with Equal-Weight Rating, Announces $131 Price Target",2019-06-11 07:08:00-04:00,LGND,neutral
759681.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,LGND,positive
759682.0,"Ligand Pharma Reports Signed License Deal Granting Cumulus Oncology Exclusive Global Rights To Develop, Commercialize VER250840 Using Co.'s VDP System; Co. To Receive Upfront License Fee, Eligible For $76M In Milestone Payments",2019-05-17 09:02:00-04:00,LGND,positive
759683.0,"Ligand Reports Purchase Of Milestone, Royalty Rights To SB206 From Novan For $12M, Will Be Entitled To Receive Tiered Royalty Of 7-10%, As Well As Up To $20M In Regulatory, Commercial Milesontes",2019-05-06 09:02:00-04:00,LGND,positive
759684.0,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen",2019-05-03 07:49:00-04:00,LGND,positive
759685.0,Ligand Pharmaceuticals Reaffirms FY19 Revenue Guidance Of $118M Which May Not Compare To The $139.25M Estimate; Affirms FY19 Adj. EPS Guidance Of $3.20 Which May Not Be Comparable To The $4.16 Estimate,2019-05-02 16:07:00-04:00,LGND,neutral
759686.0,"Ligand Pharmaceuticals Q1 EPS $1.16 Beats $1.02 Estimate, Sales $43.5M Beat $39.79M Estimate",2019-05-02 16:04:00-04:00,LGND,neutral
759687.0,Ligand Completes Enrollment Of Phase 1 Clinical Trial Of Captisol-Enabled Iohexol,2019-05-02 09:41:00-04:00,LGND,neutral
759688.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,LGND,positive
759689.0,"UPDATE: Ligand Says Will Receive Upfront Payment, Eligible To Receive Development, Commercial Milestone Payments, Royalties, No Terms Disclosed",2019-04-22 07:59:00-04:00,LGND,negative
759690.0,"UPDATE: Ligand Says Will Be Able To Use OmniAb Platform Rodents, Birds In Campaigns To Discover Fully Human Mono-, Bispecific Antibodies",2019-04-22 07:58:00-04:00,LGND,neutral
759691.0,"Ligand Pharma 8-K Shows Co. Executed, Delivered On OmniAb Platform License Deal With A Bay-Area Venture-Stage Biotech Co.",2019-04-22 07:58:00-04:00,LGND,neutral
759692.0,Ligand Reports 9.99% Stake in Seelos Therapeutics as of February 27,2019-04-15 18:19:00-04:00,LGND,neutral
759693.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,LGND,positive
759694.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-04-07 17:04:00-04:00,LGND,neutral
759695.0,Ligand Pharma Reports Will Receive $3M Milestone Payment Related To FDA Approval Of Sage Therapeutics' ZULRESSO Injection For Treatment Of PPD,2019-03-21 09:03:00-04:00,LGND,positive
759696.0,"The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed",2019-03-19 07:40:00-04:00,LGND,neutral
759697.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-03-16 08:35:00-04:00,LGND,neutral
759698.0,Ligand At Investor Day Affirmed FY19 Sales Guidance Of ~$118M,2019-03-12 10:05:00-04:00,LGND,neutral
759699.0,58 Biggest Movers From Yesterday,2019-03-07 04:55:00-05:00,LGND,neutral
759700.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-03-06 12:27:00-05:00,LGND,neutral
759701.0,Ligand Pharmaceuticals shares are trading lower after the company cut FY19 guidance and announced the sale of its Promacta assets and royalty for $827 million.,2019-03-06 11:00:00-05:00,LGND,negative
759702.0,"Ligand Adjusts FY19 Guidance: Sales ~$118M, Adj. EPS $32.25",2019-03-05 16:14:00-05:00,LGND,neutral
759703.0,"Ligand Pharma Reports Sale Of Promacta Assets, Royalty For $827M",2019-03-05 16:13:00-05:00,LGND,positive
759704.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,LGND,neutral
759705.0,Ligand Raises FY19 Sales Guidance From ~$212M To ~$224M vs $213M Estimate,2019-02-07 16:11:00-05:00,LGND,neutral
759706.0,"Ligand Pharmaceuticals Q4 EPS $1.70 Beats $1.18 Estimate, Sales $59.6M Beat $51.26M Estimate",2019-02-07 16:10:00-05:00,LGND,neutral
759707.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,LGND,neutral
759708.0,"Ligand Pharmaceuticals Says On Feb 4 Entered Into  Worldwide Commercial Platform License Agreement With Genagon Therapeutics; Genagon Gained Access To Full Omniab Transgenic Animal Technology Platform;  Ligand Eligible To Receive Milestone Payments, Tiered Royalties Of 4%-6% For Each Product Incorporating Omniab-derived Antibody",2019-02-07 06:08:00-05:00,LGND,positive
759709.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,LGND,neutral
759710.0,Ligand Pharma 8-K Shows Board Added $150M To Buyback Plan,2019-01-28 09:09:00-05:00,LGND,neutral
759711.0,"Ligand Pharma Highlights Its Partner, Seelos Therapeutics, Closed The Merger With Apricus Biosciences And Will Be Publicly Traded Under Nasdaq Symbol 'SEEL'",2019-01-25 09:01:00-05:00,LGND,neutral
759712.0,"The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US",2019-01-17 08:06:00-05:00,LGND,positive
759713.0,58 Biggest Movers From Yesterday,2019-01-17 05:27:00-05:00,LGND,neutral
759714.0,"Emmanuel Lemelson Issues Press Release Highlighting A Renewed Call For Probe In Alleged Accounting, Securities Fraud, SEC Failures At Ligand",2019-01-16 16:40:00-05:00,LGND,negative
759715.0,Ligand Pharmaceuticals Hit By Bearish Citron Report,2019-01-16 15:35:00-05:00,LGND,neutral
759716.0,'That's simply false. There are few pharma companies that disclose more information about their business in a fully transparent manner than $LGND (2/4)' -Tweet From STAT's Adam Feuerstein,2019-01-16 14:52:00-05:00,LGND,neutral
759717.0,'...on @CitronResearch $LGND report. What I found most disappointing (and fundamentally dishonest) about Andrew's work is the accusation that $LGND is lying to investors about its royalty-based business model (1/4)' -Tweet From STAT's Adam Feuerstein,2019-01-16 14:50:00-05:00,LGND,negative
759718.0,"'So, @CitronResearch short thesis on $LGND boils down to $VKTX needing to blow up. Alright, good luck, Andrew. If $VKTX pans out, you're toast, but then, he'll probably be out by then. 

The rest of the report is un-readable.' -STAT's Adam Feuerstein",2019-01-16 13:37:00-05:00,LGND,positive
759719.0,"Ligand Shares dip lower after shortseller Citron Research issued a bearish call on the stock, citing 'deception'.",2019-01-16 12:56:00-05:00,LGND,neutral
759720.0,Ligand Shares Fall ~7% Following Citron Tweet Call Co. 'The Next Valeant',2019-01-16 12:52:00-05:00,LGND,positive
759721.0,'$LGND tgt $35.  Our most comprehensive piece of pharma research since Valeant.  Citron exposes the deception behind $LGND and details the truth of their pipeline with pictures and filings.' -Tweet From Citron Research,2019-01-16 12:51:00-05:00,LGND,neutral
759722.0,Ligand Pharmaceuticals shares are trading up 3.6% after the company raised FY18 guidance.,2018-12-20 12:26:00-05:00,LGND,positive
759723.0,Ligand Pharmaceuticals shares are trading up after the company raised FY18 guidance.,2018-12-19 11:40:00-05:00,LGND,positive
759724.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,LGND,positive
759725.0,"Ligand Sees FY19 Sales At Least $212M With Up To Added $40M Of Potential Milestone, License Payments vs $204M Estimate",2018-12-18 17:01:00-05:00,LGND,neutral
759726.0,UPDATE: Ligand Pharmaceuticals Raises FY18 Adj. EPS From ~$6.52 To $6.63,2018-12-18 17:01:00-05:00,LGND,neutral
759727.0,Ligand Raises Guidance,2018-12-18 17:00:00-05:00,LGND,neutral
759728.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,LGND,positive
759729.0,Ligand Reports Purchase Of Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics For $10M,2018-12-17 16:01:00-05:00,LGND,neutral
759730.0,Sermonix Pharma Issues Press Release Highlighting FDA Accepted Its Investigational New Drug Application For Ligand's Lasofoxifene; Will Begin Phase 2 Trial For Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer,2018-12-10 10:04:00-05:00,LGND,negative
759731.0,Ligand Pharma Reports Partnership With iMetabolic Biopharma For Its OmniAb,2018-11-21 09:00:00-05:00,LGND,neutral
759732.0,"Ligand Raises FY18 Sales Guidance From $232M As Of Aug. 6, 2018 To ~$240M vs $234.8M Estimate",2018-11-08 08:16:00-05:00,LGND,neutral
759733.0,"Ligand Pharmaceuticals Incorporated Q3 EPS $1.32 Beats $1.03 Estimate, Sales $45.7M Beat $41.82M Estimate; Raises Guidance",2018-11-08 08:16:00-05:00,LGND,neutral
759734.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,LGND,negative
759735.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,LGND,neutral
759736.0,S&P Dow Jones Indices Announces Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600,2018-10-30 17:19:00-04:00,LGND,positive
759737.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,LGND,neutral
759738.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,LGND,positive
759739.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,LGND,neutral
759740.0,Ligand Pharmaceuticals  Board Approves Up to $200M Share Buyback,2018-09-24 06:22:00-04:00,LGND,positive
759741.0,10 Biggest Price Target Changes For Wednesday,2018-09-19 09:56:00-04:00,LGND,neutral
759742.0,"The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering",2018-09-19 08:47:00-04:00,LGND,negative
759743.0,"H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $270",2018-09-19 07:05:00-04:00,LGND,neutral
759744.0,"Lemelson Capital's Fr. Emmanuel Lemelson Responds To Civil Complaint Filed Against Him Today by SEC Alleging Securities Law Violations Related To Trading Ligand Pharma, Says This Matter 'Has no merit...amounts to a gross abuse of prosecutorial discretion'",2018-09-12 16:16:00-04:00,LGND,negative
759745.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,LGND,neutral
759746.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,LGND,neutral
759747.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,LGND,neutral
759748.0,"Goldman Sachs Initiates Coverage On Ligand Pharmaceuticals with Neutral Rating, Announces $256 Price Target",2018-08-17 09:03:00-04:00,LGND,neutral
759749.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,LGND,neutral
759750.0,Ligand Pharma Offers To Buy Vernalis For $43M In Cash,2018-08-09 08:16:00-04:00,LGND,neutral
759751.0,"Roth Capital Likes Ligand, But Valuation Renders Shares 'Increasingly Speculative'",2018-08-08 13:42:00-04:00,LGND,positive
759752.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,LGND,neutral
759753.0,"Benzinga's Top Upgrades, Downgrades For August 8, 2018",2018-08-08 09:12:00-04:00,LGND,positive
759754.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,LGND,positive
759755.0,Roth Capital Downgrades Ligand Pharmaceuticals to Neutral,2018-08-08 08:15:00-04:00,LGND,neutral
759756.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,LGND,negative
759757.0,Ligand Pharmaceuticals Raises FY18 Sales Guidance From $226M To $232M vs $216.58M Est.,2018-08-06 16:06:00-04:00,LGND,neutral
759758.0,"Ligand Pharmaceuticals Q2 Adj. EPS $2.59 Beats $2.34 Estimate, Sales $90M Beat $82.2M Estimate",2018-08-06 16:05:00-04:00,LGND,neutral
759759.0,"Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics In All-Stock Transaction; Apricus Shareholders To Own ~14% Of The Combined Co. With Seelos Owning ~86% Of The Combined Co.",2018-07-30 08:05:00-04:00,LGND,positive
759760.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,LGND,neutral
759761.0,"Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2",2018-07-20 07:53:00-04:00,LGND,positive
759762.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,LGND,neutral
759763.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,LGND,neutral
759764.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,LGND,positive
759765.0,Ligand Raises FY18 Sales Guidance From $184M To $226M vs $188.2M Estimate,2018-06-27 09:04:00-04:00,LGND,neutral
759766.0,Ligand Pharma Reports Received $47M From WuXi Biologics For Expansion Of Global OmniAb Platform License Deal,2018-06-27 09:04:00-04:00,LGND,neutral
759767.0,"Benzinga's Top Upgrades, Downgrades For June 21, 2018",2018-06-21 08:57:00-04:00,LGND,positive
759768.0,"Argus Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces $260 Price Target",2018-06-21 07:33:00-04:00,LGND,neutral
759769.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,LGND,positive
759770.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,LGND,neutral
759771.0,"Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings",2018-05-16 08:10:00-04:00,LGND,neutral
759772.0,"UPDATE: Ligand Pharma Will Receive Undisclosed Upfront Payment, Is Eligible To Receive Annual Platform Access Payments, Development, Regulatory Milestone Payments",2018-05-10 06:52:00-04:00,LGND,neutral
759773.0,"Ligand Pharmaceuticals Says Entered Commercial Platform License Agreement, With KSQ Therapeutics",2018-05-10 06:52:00-04:00,LGND,positive
759774.0,Ligand Pharma 8-K Shows Co. Entered Commercial Platform License Agreement With KSQ Under Which KSQ Will Be Able To Use Co.'s Full OmniAb Platform To Discover Antibodies,2018-05-10 06:52:00-04:00,LGND,positive
759775.0,"Ligand Pharmaceuticals Q1 Adj. EPS $1.55 Beats $1.15 Estimate, Sales $56.2M Beat $42.69M Estimate",2018-05-08 16:03:00-04:00,LGND,neutral
759776.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,LGND,neutral
759777.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,LGND,neutral
759779.0,"H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $182.00",2018-03-07 09:47:00-05:00,LGND,neutral
759780.0,Ligand Pharmaceuticals Says‍ Underreported Potential Aggregate Milestone Payments Related to License Agreement With Roivant Sciences for LGD-6972; Ligand Pharma to Receive Potential License & Milestone Payments Up to $548.8M -8K,2018-03-07 06:20:00-05:00,LGND,positive
759781.0,Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences,2018-03-06 16:14:00-05:00,LGND,negative
759782.0,"Ligand Pharma Sees FY18 Adj. EPS $4.22 vs $4.42 Est., Sales $164M vs $166.88M Est.",2018-02-21 16:02:00-05:00,LGND,neutral
759783.0,"Ligand Pharma Reports Q4 Adj. EPS $1.31 vs $1.14 Est., Sales $50.5M vs $47.82M Est.",2018-02-21 16:01:00-05:00,LGND,neutral
759784.0,Ligand Pharmaceuticals Q4 Earnings Preview,2018-02-21 10:40:00-05:00,LGND,neutral
759785.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,LGND,neutral
759786.0,"Ligand Pharma Shares Continue Higher Tues., Up 2%; Stock Up 19% YTD; Form 4 Filing Late Mon. From CEO John Higgins Showed Exercise Of ~16K Shares, Sale Of 11.85K Shares On Jan. 19",2018-01-23 12:56:00-05:00,LGND,positive
759787.0,Ligand Enters into Worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals,2018-01-22 09:01:00-05:00,LGND,positive
759788.0,"Ligand Pharma Reports Established Program To Develop Captisol-Enabled, Next-Gen Contrast Agents For Diagnostic Imaging",2018-01-18 16:01:00-05:00,LGND,neutral
759789.0,Ligand Pharma Reports Entered Into Global OmniAb Platform License Deal With Glenmark Pharma,2018-01-11 09:03:00-05:00,LGND,neutral
759790.0,Ligand Pharma Reports Earned $6M As OmniAb Partner Out-Licenses Antibody Projects,2018-01-03 09:02:00-05:00,LGND,neutral
759791.0,35 Biggest Movers From Yesterday,2017-11-21 05:10:00-05:00,LGND,neutral
759792.0,Mid-Afternoon Market Update: Dow Gains 90 Points; Micronet Enertec Technologies Shares Drop,2017-11-20 14:32:00-05:00,LGND,positive
759793.0,32 Stocks Moving In Monday's Mid-Day Session,2017-11-20 12:30:00-05:00,LGND,neutral
759794.0,Mid-Day Market Update: Crude Oil Down 1%; Northern Technologies Shares Surge After Q4 Results,2017-11-20 12:00:00-05:00,LGND,negative
759795.0,Mid-Morning Market Update: Markets Open Higher; Marvell To Buy Cavium For $6B,2017-11-20 10:14:00-05:00,LGND,neutral
759796.0,"Benzinga's Top Upgrades, Downgrades For November 20, 2017",2017-11-20 09:05:00-05:00,LGND,positive
759797.0,Deutsche Bank Downgrades Ligand Pharmaceuticals to Sell,2017-11-20 06:43:00-05:00,LGND,neutral
759798.0,"Ligand Pharmaceuticals Sees FY17 Adj. EPS $2.95-$3 vs $2.95 Est., Sales $134M-$136M vs $134.35M Est.",2017-11-14 17:28:00-05:00,LGND,neutral
759799.0,Ligand Pharmaceuticals and Boingo Wireless Holding Analyst/Investor Days Today,2017-11-14 09:38:00-05:00,LGND,neutral
759800.0,"The Week Ahead For November 13: Conferences, Earnings and IPO Events To Watch",2017-11-13 09:36:00-05:00,LGND,neutral
759801.0,"Ligand Announces an Agreement to License its Captisol to Meridian Labs, Ligand Could Receive Payment from Licenses, Royalties or Milestone Payments",2017-11-13 08:18:00-05:00,LGND,positive
759802.0,"Ligand Updates FY17 Outlook, Raises Adj. EPS From $2.93 to $2.95-$3 vs $2.95 Est., Sales From $134M vs $134M-$136M vs $134.55M Est.",2017-11-09 16:20:00-05:00,LGND,neutral
759803.0,Ligand Pharma Reports Q3 Adj. EPS $0.69 vs $0.61 Est.,2017-11-09 16:01:00-05:00,LGND,neutral
759804.0,"H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $159.00",2017-11-09 08:55:00-05:00,LGND,neutral
759805.0,Ligand Pharma Reports Purchase Of Crystal Bioscience For $25M In Cash Plus added Potential Payments Of Up To $10.5M,2017-10-04 16:05:00-04:00,LGND,neutral
759806.0,"Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ",2017-09-06 09:13:00-04:00,LGND,neutral
759807.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2017",2017-09-05 09:19:00-04:00,LGND,positive
759808.0,Analyst Makes The Case For Ligand As A 'Core' Holding,2017-09-05 08:49:00-04:00,LGND,neutral
759809.0,Ligand Pharma Phase 2 Study of LGD-6972 Met Primary Endpoint,2017-09-05 08:11:00-04:00,LGND,neutral
759810.0,"H.C. Wainwright Assumes Ligand Pharmaceuticals at Buy, Announces price target $150.00",2017-09-05 07:03:00-04:00,LGND,neutral
759811.0,Ligand to Receive $2M from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb Technology,2017-08-18 09:01:00-04:00,LGND,neutral
759812.0,"Ligand Pharmaceuticals Reports Q2 Adj. EPS $0.67 vs $0.46 Est., Sales $28M vs $24.07M Est.",2017-08-07 16:04:00-04:00,LGND,neutral
759813.0,"Ligand Enters Into Commercial License, Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330",2017-07-17 09:01:00-04:00,LGND,positive
759814.0,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 11:01:00-04:00,LGND,neutral
759816.0,"Ligand Reports Melinta Therapeutics Received FDA Approval For Baxdeal For Acute Bacterial Skin, Skin Structure Infections",2017-06-20 09:01:00-04:00,LGND,positive
759818.0,"Jefferies Health Care Conference Continues Today, Presenters Include: Ligand, Immunogen, TherapeuticsMD, Synergy Pharma, Ironwood, Acadia, Community Health Systems, & Celldex",2017-06-08 08:37:00-04:00,LGND,positive
759819.0,Ligand Enters into Worldwide OmniAb Platform License Agreement with Surface Oncology,2017-06-01 09:02:00-04:00,LGND,positive
759820.0,"UPDATE: Ligand Announces, as Part of Royalty Rate Reduction, Aziyo Agreed to Pay Co. Up to $10M of Added  Sales-Based Milestones Tied to Commercial Success of Currently-Marketed Products",2017-05-31 17:36:00-04:00,LGND,positive
759821.0,Ligand Reports Received $10M from Contractually Specified Royalty Rate Buy-Down Following Sale by CorMatrix,2017-05-31 17:36:00-04:00,LGND,neutral
759822.0,"Craig-Hallum Institutional Investor Conference Takes Place Today, Attendees Include: Auxilio, TrueCar, Ligand Pharma, 8x8, MACOM Technology, NetScout Systems",2017-05-31 09:35:00-04:00,LGND,neutral
759823.0,Ligand Enters Into Worldwide OmniAb Platform License Agreement With xCella Biosciences,2017-05-30 09:01:00-04:00,LGND,positive
759824.0,Tracking The Busy June PDUFA Calendar,2017-05-30 08:58:00-04:00,LGND,neutral
759825.0,"Companies Holding Shareholder Meetings Today Include: Acadia Healthcare, Big Lots, Arconic, Axon Enterprise, AK Steel, Cinemark, Green Dot, Fitbit, Ligand Pharmaceuticals, Norwegian Cruise Line, Raytheon, & Tiffany",2017-05-25 08:38:00-04:00,LGND,neutral
759826.0,"8-K from Ligand Pharma Shows Co. Entered License, Supply Deal with AnalgesiX Granting IAX Exclusive Right to Use Captisol in IAX's Development, Commercialization of Captisol-Enabled Version of Specified Compound",2017-05-23 16:17:00-04:00,LGND,positive
759827.0,"Ligand Affirms FY17 Outlook: Core Sales of $130M vs $133.9M Est., Adj. EPS ~$2.70 vs $2.71 Est.",2017-05-09 16:05:00-04:00,LGND,neutral
759828.0,"Ligand Reports Q1 Adj. EPS $0.57 vs $0.63 Est., Sales $29.3M vs $31.2M Est.",2017-05-09 16:04:00-04:00,LGND,neutral
759829.0,"Ligand Enters Commercial License, Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone",2017-04-05 09:01:00-04:00,LGND,positive
759830.0,"Ligand Pharma Announces Licensing Partner Janssen Filed IND for Antibody Discovered Using OmniAb Technology, Results in $1M Milestone Payment",2017-03-28 09:03:00-04:00,LGND,neutral
759831.0,"8-K from Ligand Pharma Highlights Co. is Eligible to Receive $1.6M Upon Initiation of Retrophin's Phase 3 Trial o f Sparsentan, ~$5.99M Upon Filing of NDA in FSGS, Potential Net Milestones of $65M+ in the Future, 9% Net Royalties",2017-03-03 09:09:00-05:00,LGND,neutral
759832.0,Ligand Expands License With Sermonix To Include Worldwide Rights For Oral Lasofoxifene,2017-02-28 16:02:00-05:00,LGND,positive
759833.0,"Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Increasing From U.S., Japan",2017-02-28 08:27:00-05:00,LGND,positive
759834.0,Ligand Holding Analyst Day Today,2017-02-28 06:56:00-05:00,LGND,neutral
759835.0,Roth Capital Reinstates Ligand Pharmaceuticals With Buy,2017-02-27 08:57:00-05:00,LGND,neutral
759836.0,"Ligand Reports Q4 Adj. EPS $0.74 vs $1.19 Est., Sales $38.2M vs $40.34M Est.",2017-02-23 16:04:00-05:00,LGND,neutral
759837.0,"Emmanuel Lemelson Responds to Ligand's After-Hours 8-K, Tells Benzinga Filing 'may   be indicative of a significant and material impact on the financials and perhaps yet another significant restatement by the company'",2017-01-18 16:49:00-05:00,LGND,positive
759838.0,"UPDATE: Ligand Says 'expects to recognize royalties on sales of products commercialized by its partners when those products are sold by the partner, rather than when such payments are reported to the Company'",2017-01-18 16:30:00-05:00,LGND,neutral
759839.0,UPDATE: Ligand Says Expects Revenue Related to Captisol Material Sales to Remain Unchanged,2017-01-18 16:29:00-05:00,LGND,neutral
759840.0,"UPDATE: Ligand Says Anticipates FASB Standard Will Have Most Significant Impact Related to Co. 'accounting for revenues related to royalties, and contingent ""milestone"" based payments'",2017-01-18 16:29:00-05:00,LGND,positive
759841.0,"UPDATE: Ligand Highlights FASB Accounting Standards Codification Topic 606 Must Be Adopted After Jan. 1, '17, No Later Than Jan. 1, '18; Says Standards Will Have Material Impact on Financial Statements",2017-01-18 16:28:00-05:00,LGND,negative
759842.0,Ligand Pharma Issues 8-K,2017-01-18 16:25:00-05:00,LGND,neutral
759843.0,"Ligand Reports Entering of Commercial License, Supply Deal for Captisol-Enabled Trametinib",2016-12-22 09:16:00-05:00,LGND,neutral
759844.0,Ligand Enters License Agreemtn With Ono Pharmaceutical,2016-12-22 08:30:00-05:00,LGND,neutral
759845.0,Lemelson On Ligand: Intrinsic Value Is Zero,2016-12-21 16:26:00-05:00,LGND,positive
759846.0,Rev. Emmanuel Lemelson Tells Benzinga Intrinsic Value on Ligand is $0,2016-12-21 15:31:00-05:00,LGND,positive
759847.0,Lantern Foundation's Emmanuel Lamelson Issues Press Release on Ligand: 'Urges Senate Committee to Commence Investigation into Ligand',2016-12-21 14:01:00-05:00,LGND,neutral
759848.0,Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016,2016-11-21 07:30:00-05:00,LGND,positive
759849.0,Ligand Pharma Files for Non-Timely 10-Q,2016-11-09 08:33:00-05:00,LGND,neutral
759850.0,"Ligand Reports Q3 Adj EPS $0.62 vs $0.59 Est, Rev $21.6M vs $23.13M Est",2016-11-03 16:02:00-04:00,LGND,neutral
759851.0,Ligand Pharma Announces Partner Melinta Therapeutics Submitted Baxdeal NDA for Hospital-Treated Skin Infections,2016-10-24 09:22:00-04:00,LGND,neutral
759852.0,Ligand Pharmaceuticals -8% @$103.85,2016-09-27 09:34:00-04:00,LGND,neutral
759853.0,Ligand Reports Licensing of Four Programs to Seelos Therapeutics,2016-09-22 09:00:00-04:00,LGND,neutral
759854.0,Ligand Reports OmniAb License Deal with TeneoBio,2016-09-16 09:01:00-04:00,LGND,neutral
759855.0,Ligand Reports Initiation of Phase 2 Trial with LGD-6972 in Type 2 Diabetes,2016-09-13 08:30:00-04:00,LGND,neutral
759856.0,"Martin Shkreli on Ligand Valuation: Stock 'Doesn't Look Cheap, But I Don't Know If I'd Run Out and Short It'",2016-09-12 08:28:00-04:00,LGND,neutral
759857.0,"Martin Shkreli on Pharma Co./Stock Valuation: Discussing Ligand, Thinks Mgmt 'Runs a Really Good Co.,' But Highlights There is Always a Chance for a Discrepancy with Co. and Stock Valuation",2016-09-12 08:26:00-04:00,LGND,positive
759858.0,18 Biggest Mid-Day Gainers For Wednesday,2016-09-07 12:58:00-04:00,LGND,neutral
759859.0,"Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'",2016-09-07 10:57:00-04:00,LGND,positive
759860.0,Benzinga's Top Upgrades,2016-09-07 08:57:00-04:00,LGND,positive
759861.0,The Market In 5 Minutes: All Eyes On Apple's New iPhone And Ackman's New Chipotle Stake,2016-09-07 08:38:00-04:00,LGND,neutral
759862.0,Deutsche Bank Upgrades Ligand Pharmaceuticals to Hold,2016-09-07 07:00:00-04:00,LGND,neutral
759863.0,Rough Month: A Closer Look At Ligand's Fall From All-Time Highs,2016-08-24 15:49:00-04:00,LGND,neutral
759864.0,Technical Alert: Sellers Flood Ligand Pharmaceuticals In Sympathy With Mylan Labs Decline,2016-08-24 15:29:00-04:00,LGND,positive
759865.0,"Downside in Ligand Pharma Shares Intensifies as $106 Level Breached, Stock Down 3.2% for Session; Traders May Be Viewing Stock as Sympathy Play on Mylan Drug Price Increase Debate",2016-08-24 14:18:00-04:00,LGND,positive
759866.0,Ligand Down 20% Since August 1; What's The Street Thinking?,2016-08-17 15:16:00-04:00,LGND,neutral
759867.0,Technical Alert: Horrible August For Ligand Pharmaceuticals Continues,2016-08-17 12:17:00-04:00,LGND,negative
759868.0,"Ligand Pharma Reports Results from Phase 1 Trials with Co.'s LGD-6972 in Type 2 Diabetes Mellitus Published in Paper: Showed Favorable Safety, Tolerability, Pharmacokinetics, Improved Glycemic Response",2016-08-15 09:02:00-04:00,LGND,positive
759869.0,"Ligand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says",2016-08-11 14:33:00-04:00,LGND,neutral
759870.0,Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging,2016-08-05 14:25:00-04:00,LGND,positive
759871.0,Deutsche Bank Downgrades Ligand Pharmaceuticals to Sell,2016-08-05 06:20:00-04:00,LGND,neutral
759872.0,"Ligand Affirms FY16 Outlook: Adj EPS $3.41-$3.46 vs $3.30 Est., Sales $115M-$119M vs $116M Est.",2016-08-04 08:07:00-04:00,LGND,neutral
759873.0,"Ligand Reports Q2 Adj. EPS $0.50 vs $0.40 Est., Sales $19.5M vs $18M Est.",2016-08-04 08:06:00-04:00,LGND,neutral
759874.0,Ligand Reports Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals,2016-07-29 08:34:00-04:00,LGND,positive
759875.0,Adam Feuerstein Tweets '$LGND — derivative play off $SAGE data. Captisol is used to soluble '547.',2016-07-12 09:08:00-04:00,LGND,positive
759876.0,Ligand Reaches OmniAb Platform License Agreement with Gilead,2016-07-08 11:12:00-04:00,LGND,positive
759877.0,Ligand Enters into OmniAb Platform License Agreement with Gilead Sciences,2016-07-08 09:01:00-04:00,LGND,positive
759878.0,"Ligand Receives $4 Million from Expansion of Two OmniAb License Agreements, Sees Q2 Rev. Of $19M vs. Est. $18.12M",2016-06-30 16:03:00-04:00,LGND,positive
759879.0,"Ligand Pharma Shares Giving Back Some of Last Three Day's Rally; Had Rallied ~8.7% This Week, Down ~2.6% Thurs.",2016-06-30 14:16:00-04:00,LGND,positive
759880.0,Ligand Pharmaceuticals Q1 Adjusted Earnings Beat,2016-05-04 07:16:00-04:00,LGND,neutral
759881.0,"Ligand Sees FY16 Adj. EPS $3.41-$3.46 vs $3.37 Est., Sales $115M-$119M vs $118.5M Est.",2016-05-04 06:44:00-04:00,LGND,neutral
759882.0,"Ligand Pharma Reports Q1 Adj. EPS $0.97 vs $0.67 Est., Sales $29.6M vs $26.5M Est.",2016-05-04 06:44:00-04:00,LGND,neutral
759883.0,Ligand Pharma Announces Synthetic Rights from CoreMatrix for $17.5M,2016-05-04 06:00:00-04:00,LGND,neutral
759884.0,Roth Capital Reiterates $147 Price Target & Buy Rating  And Recommends Steady Accumulation Of Shares,2016-04-22 14:03:00-04:00,LGND,positive
759885.0,"UPDATE: Under Original FDA Submission by Lundbeck in 2014, Ligand was to Earn a $200K Milestone Payment",2016-04-22 13:24:00-04:00,LGND,positive
759886.0,FDA Accepts Lundbeck Resubmission of NDA for Carnexiv (Carbamazepine),2016-04-22 13:14:00-04:00,LGND,positive
759887.0,Viking Therapeutics Issues 960K Shares and a Warrant for 960K Shares to Ligand Pharma Per Previous Loan Agreement,2016-04-14 06:27:00-04:00,LGND,positive
759888.0,"Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017",2016-04-13 09:33:00-04:00,LGND,neutral
759889.0,"Stephens & Co. Initiates Coverage on Ligand Pharmaceuticals at Overweight, Announces $150.00 PT",2016-04-13 08:38:00-04:00,LGND,negative
759890.0,Analyst Says Viking Therapeutics Can Quadruple Because Of Its Relationship With Ligand Scientists,2016-04-07 14:35:00-04:00,LGND,neutral
759891.0,Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It,2016-04-07 09:46:00-04:00,LGND,positive
759892.0,Ligand Pharma Announces Revolade Approved in US as First-in-Class Therapy for Children 1+ with Chronic ITP,2016-04-07 09:01:00-04:00,LGND,positive
759893.0,Ligand Pharma Reports Entered Into OmniAb Platform License Deal with ABBA Therapeutics,2016-03-28 09:02:00-04:00,LGND,neutral
759894.0,Ligand Enters Into OmniAb Platform License Agreement With ABBA Therapeutics,2016-03-28 09:01:00-04:00,LGND,positive
759895.0,"Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA for Injection, Will Receive $6M Milestone",2016-03-15 09:00:00-04:00,LGND,positive
759896.0,"Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises PT to $147.00",2016-03-11 09:01:00-05:00,LGND,neutral
759897.0,Benzinga's Top Initiations,2016-03-03 10:01:00-05:00,LGND,positive
759898.0,Buy Ligand Shares; HC Wainwright Sets $146 Price Target,2016-03-03 09:04:00-05:00,LGND,positive
759899.0,"HC Wainwright Says Ligand 'is all about sustainable revenues and earnings growth', Calls OmniAb Acquisition 'transformative for Ligand'",2016-03-03 07:15:00-05:00,LGND,neutral
759900.0,"H.C. Wainwright Initiates Coverage on Ligand Pharmaceuticals at Buy, Announces $146.00 PT",2016-03-03 07:14:00-05:00,LGND,neutral
759901.0,"Ligand Reports Q4 EPS $0.66 vs. Est. $0.65, Rev. $21.2M vs. Est. $24.97M",2016-02-10 16:02:00-05:00,LGND,neutral
759902.0,"Ligand Pharma, Tizona Therapeutics Enter Platform License Agreement",2016-02-02 09:00:00-05:00,LGND,positive
759903.0,Ligand Reports OmniAb Platform Licensing Deal with Emergent BioSolutions,2016-01-13 09:45:00-05:00,LGND,neutral
759904.0,Filing from Ligand Pharma Shows Registration for ~$180.066M Offering of Common Stock via Selling Holders,2016-01-08 16:11:00-05:00,LGND,neutral
759905.0,Roth Capital's Joseph Pantginis Reiterates Buy on Ligand Following Captisol Supply Deal with Gilead; 'We believe Ligand is strongly positioned for continued growth.',2015-12-31 09:51:00-05:00,LGND,positive
759906.0,8-K from Ligand Pharma Shows Co. Entered Supply Deal with Gilead for Captisol,2015-12-31 08:29:00-05:00,LGND,neutral
759907.0,Shares of Ligand Pharma to Resume Trade at 4:30 p.m. EST,2015-12-17 16:07:00-05:00,LGND,positive
759908.0,UPDATE: Ligand Acquisition Of OMT Expected To Be Accretive To Rev. And Adj. EPS,2015-12-17 16:03:00-05:00,LGND,neutral
759909.0,"UPDATE: Ligand Deal To Be $92.6M Cash, $85.4M Ligand Common Stock",2015-12-17 16:01:00-05:00,LGND,neutral
759910.0,Ligand To Acquire OMT For $178M Cash & Stock,2015-12-17 16:01:00-05:00,LGND,neutral
759911.0,"Ligand Pharma, RODES Report Signing of Exclusive Captisol Licensing Deal for Three Programs",2015-12-08 07:33:00-05:00,LGND,positive
759912.0,"UPDATE: Ligand Highlights 'Upwards of $1.8B in Partner R&D to Be Spent' on 125+ Programs, 72+ Cos.",2015-11-18 16:05:00-05:00,LGND,neutral
759913.0,"Ligand Sees FY16 Rev. $107-$111M vs. Est. $107.4M, EPS $3.33-$3.38 vs. Est. $3.15",2015-11-18 16:05:00-05:00,LGND,neutral
759914.0,"Ligand Sees FY17 Rev. Greater Than $146M, Adj. EPS Greater Than $4.75/Share",2015-11-18 16:04:00-05:00,LGND,positive
759915.0,"Ligand Sees FY12-FY17 Sales Growth on CAGR Basis 36%, Adj. EPS 79%",2015-11-18 16:03:00-05:00,LGND,positive
759916.0,"Ligand Sees FY15 Adj. EPS $3.34-$3.37 vs $3.52 Est., Sales $75M-$76M vs $82.4M Est.",2015-11-09 16:04:00-05:00,LGND,neutral
759917.0,"Ligand Sees Q4 Adj. EPS $0.63-$0.66 vs $0.95 Est., Sales $24.3M-$25.3M vs $31.6M Est.",2015-11-09 16:03:00-05:00,LGND,neutral
759918.0,"Ligand Pharma Reports Q3 Adj. EPS $0.56 vs $0.42 Est., Sales $17.7M vs $17.8M Est.",2015-11-09 16:03:00-05:00,LGND,neutral
759919.0,Spectrum Pharmaceuticals Receives CRL from FDA for EVOMELA for Injection,2015-10-23 04:22:00-04:00,LGND,neutral
759920.0,Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689,2015-09-29 09:02:00-04:00,LGND,positive
759921.0,8-K from Ligand Pharma Shows Board Approved $200M Buyback Plan,2015-09-16 16:15:00-04:00,LGND,positive
759922.0,Revolade Gets EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia,2015-09-02 09:01:00-04:00,LGND,positive
759923.0,FDA Increases Use of Promacta to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia,2015-08-24 13:00:00-04:00,LGND,positive
759924.0,Ligand Affirms FY15 Outlook,2015-08-04 16:02:00-04:00,LGND,neutral
759925.0,"Ligand Pharma Reports Q2 Adj. EPS $1.81, Sales $18.4M vs $17M Est.",2015-08-04 16:00:00-04:00,LGND,neutral
759926.0,"Ligand Pharma Announces Entering Into of Commercial Licensing, Supply Deal with Sanofi for Capitsol-Enabled SAR-125844",2015-07-30 09:02:00-04:00,LGND,neutral
759927.0,Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma,2015-07-29 15:18:00-04:00,LGND,neutral
759928.0,"Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder",2015-07-24 09:02:00-04:00,LGND,positive
759929.0,Cantor Boosts Ligand Pharma Target To $93,2015-06-19 11:07:00-04:00,LGND,positive
759930.0,Deutsche Bank Cuts Ligand Pharma To Hold,2015-06-15 10:41:00-04:00,LGND,negative
759931.0,Benzinga's Top Downgrades,2015-06-15 10:03:00-04:00,LGND,positive
759932.0,Deutsche Bank Downgrades Ligand Pharmaceuticals To  Hold,2015-06-15 08:10:00-04:00,LGND,neutral
759933.0,Deutsche Bank Downgrades Ligand Pharmaceuticals to Hold,2015-06-15 06:32:00-04:00,LGND,neutral
759934.0,FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication,2015-06-12 08:01:00-04:00,LGND,positive
759935.0,Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes,2015-06-07 18:45:00-04:00,LGND,positive
759936.0,"Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'",2015-06-07 11:20:00-04:00,LGND,positive
759937.0,UPDATE: Ligand Adjusts FY15 EPS Guidance from $2.14-$2.18 Previously to $3.45-$3.50 (Which Accounts for Viking IPO),2015-06-02 16:32:00-04:00,LGND,neutral
759938.0,"UPDATE: Ligand Sees $28.2M of Non-Operating Income During Q2 Related to 'Gain on Deconsolidation' from Viking IPO; Affirms Q2, FY15 Sales Guidance, Adjusts EPS Outlook",2015-06-02 16:31:00-04:00,LGND,positive
759939.0,"Ligand Offers Update on Impact of Viking Therapeutics IPO, Updates FY15 Outlook",2015-06-02 16:30:00-04:00,LGND,neutral
759940.0,"Ligand Pharma Reports Q1 GAAP EPS $0.04, Adj. EPS $0.33 vs $0.27 Est., Sales $14.6M vs $13.5M Est.; Sees Q2 Sales $17M-$17.5M vs $16.4M Est.",2015-05-11 08:30:00-04:00,LGND,neutral
759941.0,Ligand Acquires Rights to More Than 15 Development Programs from Selexis SA,2015-05-11 08:16:00-04:00,LGND,neutral
759942.0,"Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering, 3M Shares @ $8/Shr",2015-05-05 08:13:00-04:00,LGND,positive
759943.0,Ligand Partner Viking Therapeutics Announces Pricing of 3M Shares At $8.00/Share,2015-04-29 08:12:00-04:00,LGND,positive
759944.0,Ligand Pharma Names Melanie Herman as Interim CFO,2015-04-23 16:26:00-04:00,LGND,neutral
759945.0,Ligand Pharma Earns $500K Milestone From SAGE Therapeutics By Start Of Phase 3 Clinical Program For SAGE-547,2015-04-22 12:01:00-04:00,LGND,neutral
759946.0,Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds,2015-04-20 07:41:00-04:00,LGND,positive
759947.0,"Ligand Pharma, Metabasis Therapeutics Entered Into Amended Master License Agreement With Viking Therapeutics",2015-04-10 08:59:00-04:00,LGND,positive
759948.0,Spectrum Pharmaceuticals Says Evomela Stability Shown to be Significantly Longer Than Current Melphalan HCL for Injection,2015-03-30 07:08:00-04:00,LGND,neutral
759949.0,Spectrum Pharmaceuticals Announces FDA Accepts NDA Filing for Captisol-Enabled Melphalan,2015-03-09 07:03:00-04:00,LGND,positive
759950.0,CRT Capital Initiates Ligand Pharmaceuticals With Buy,2015-03-03 09:24:00-05:00,LGND,neutral
759951.0,Benzinga's Top Initiations,2015-03-03 09:07:00-05:00,LGND,positive
759952.0,"CRT Capital Initiates Coverage on Ligand Pharmaceuticals at Buy, Announces $102.00 PT",2015-03-03 04:59:00-05:00,LGND,neutral
759953.0,Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled Melphalan at 2015 BMT Tandem Meeting,2015-02-12 07:05:00-05:00,LGND,neutral
759954.0,What's GlaxoSmithKline Doing In The E.U.?,2015-02-09 21:13:00-05:00,LGND,neutral
759955.0,Ligand Pharmaceuticals Sees FY2017 Sales $146.0M,2015-02-09 12:04:00-05:00,LGND,neutral
759956.0,Ligand Pharmaceuticals Sees FY2016 Sales $107.0M,2015-02-09 12:04:00-05:00,LGND,neutral
759957.0,Morning Market Losers,2015-02-09 10:00:00-05:00,LGND,negative
759958.0,"UPDATE: Ligand Pharmaceuticals Posts In-Line Q4 Earnings, Issues Weak Outlook",2015-02-09 09:17:00-05:00,LGND,negative
759959.0,"Ligand Pharma Reports Q4 Adj. EPS $0.60, Inline; Sees Q1 Adj. EPS $0.25-$0.27, Sales $13M-$13.5M; Reaffirms FY Outlook",2015-02-09 08:31:00-05:00,LGND,neutral
759960.0,"Earnings Scheduled For February 9, 2015",2015-02-09 04:58:00-05:00,LGND,neutral
759961.0,Should Ligand Pharmaceuticals Worry Investors?,2015-02-06 13:22:00-05:00,LGND,negative
759962.0,Ligand Signs License Agreement With Sermonix for Lasofoxifene,2015-02-03 08:32:00-05:00,LGND,positive
759963.0,Ligand Promotes Matthew W. Foehr to President,2015-02-02 16:34:00-05:00,LGND,positive
759964.0,Tech Stock Strategist Sean Udall's Take On Apple's Earnings Report,2015-01-27 09:50:00-05:00,LGND,neutral
759965.0,#Premarket Prep Technical Update - Apple Lower,2015-01-12 14:12:00-05:00,LGND,negative
759966.0,Retrophin Receives Orphan Drug Designation For Sparsentan,2015-01-09 10:16:00-05:00,LGND,neutral
759967.0,Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results For Delafloxacin IV,2015-01-08 08:34:00-05:00,LGND,positive
759968.0,Spectrum Pharmaceuticals Files NDA with the FDA for Captisol-Enabled Melphalan,2014-12-26 07:00:00-05:00,LGND,neutral
759969.0,Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication For Promacta,2014-12-22 09:21:00-05:00,LGND,neutral
759970.0,Pfizer Receives EU Marketing Authorization for DUAVIVE; Ligan Entitled to Milestone Payment Following Pfizer Obtaining Pricing of DUAVIVE in Major European Market,2014-12-19 11:37:00-05:00,LGND,positive
759971.0,UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On Biopharma,2014-12-02 08:05:00-05:00,LGND,positive
759972.0,"Deutsche Bank Initiates Coverage on Ligand Pharmaceuticals Incorporated at Buy, Announces $74.00 PT",2014-12-02 06:31:00-05:00,LGND,neutral
759973.0,Hedge Fund Guru Emmanuel Lemelson Just Revealed How He's Trading Apple (And 3 Other Stocks),2014-11-19 11:45:00-05:00,LGND,neutral
759974.0,Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak Guidance,2014-11-18 15:56:00-05:00,LGND,negative
759975.0,"Ligand Release Offers Highlights from Analyst Day: Expecting FY15 Sales in $81-$83M Range vs $91.9M Est., Sees FY16 Sales Exceeding $107M, Adj. EPS Exceeding $3.20, Sees FY17 Sales Exceeding $146M, Adj. EPS Exceeding $4.65",2014-11-18 11:44:00-05:00,LGND,neutral
759976.0,From 8-K: Ligand Pharmaceuticals Incorporated Sees FY2015 EPS $2.14-2.18 vs $2.42 Est,2014-11-18 10:15:00-05:00,LGND,neutral
759977.0,Ligand Reports Partner GSK Has EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade,2014-11-12 09:17:00-05:00,LGND,negative
759978.0,UPDATE: Ligand Pharmaceuticals Q3 Earnings Beat Street View,2014-10-27 09:00:00-04:00,LGND,neutral
759979.0,Ligand Pharmaceuticals Incorporated Sees FY2014 EPS $1.50-1.55 vs $1.54 Est; Sees Sales $64.0M-66.0M vs $64.60M Est,2014-10-27 08:02:00-04:00,LGND,neutral
759980.0,Ligand Pharmaceuticals Incorporated Sees Q4 EPS $0.57-0.62; Sees Sales $22.50M-24.50M,2014-10-27 08:01:00-04:00,LGND,neutral
759981.0,Ligand Pharmaceuticals Incorporated Reports Q3 EPS of $0.36 vs $0.31 Est; Revenue of $15.0M vs $14.56M Est,2014-10-27 08:00:00-04:00,LGND,neutral
759982.0,Why Lemelson Capital Is Short On Ligand Pharmaceuticals,2014-10-17 15:52:00-04:00,LGND,neutral
759983.0,Dow Surges Over 200 Points After FOMC Minutes; Blackhawk Shares Jump On Strong Results,2014-10-08 15:40:00-04:00,LGND,positive
759984.0,Interface Drops On Q3 Warning; Symantec Shares Rise,2014-10-08 14:03:00-04:00,LGND,negative
759985.0,Ligand Pharmaceuticals Inc. Shares Gain On Q3 Pre-Announcement,2014-10-08 11:35:00-04:00,LGND,positive
759986.0,Mid-Morning Market Update: Markets Mostly Flat; Costco Posts Upbeat Earnings,2014-10-08 10:00:00-04:00,LGND,neutral
759987.0,Morning Market Movers ,2014-10-08 09:36:00-04:00,LGND,neutral
759988.0,Ligand Pharmaceuticals Incorporated Sees FY2014 EPS $1.50-1.55 vs $1.55 Est; Sees Sales $64.0M-66.0M vs $64.20M Est,2014-10-08 08:33:00-04:00,LGND,neutral
759989.0,Ligand Pharmaceuticals Incorporated Sees Q4 Sales $22.50M-24.50M vs $23.50M Est,2014-10-08 08:33:00-04:00,LGND,neutral
759990.0,Ligand Pharmaceuticals Incorporated Raises Q3 EPS Guidance from $0.26-0.29 to $0.33-0.37 vs $0.32 Est; Raises Q3 Sales Guidance from $13.0M-14.0M to $15.0M vs $14.20M Est,2014-10-08 08:31:00-04:00,LGND,neutral
759991.0,Ligand Earns $550K Milestone Payment Triggered by EU Approval of Merck's Captisol-enabled NOXAFIL ,2014-09-26 08:31:00-04:00,LGND,positive
759992.0,"Ligand Licenses Captisol-Enabled Lamotrigine to CURx Pharma, Will Receive $22M in Potential Milestone Payments",2014-09-09 08:31:00-04:00,LGND,neutral
759993.0,Ligand Announces Partner GlaxoSmithKline Has Received FDA Approval for Promacta/Revolade,2014-08-27 08:00:00-04:00,LGND,positive
759994.0,Lemelson Capital Comments On Ligand Debt Offering ,2014-08-25 11:46:00-04:00,LGND,negative
759995.0,"UPDATE: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment",2014-08-15 09:33:00-04:00,LGND,positive
759996.0,"Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment",2014-08-15 09:32:00-04:00,LGND,positive
759997.0,"Lemelson Capital Issues Report 'Ligand Pharma's $225M Debt Issuance Solidifies Company's Insolvancy, Substantially Raises Specter of Bankruptcy'",2014-08-14 10:46:00-04:00,LGND,negative
759998.0,Ligand Pharma Reports Signing of Multi-Program Captisol License Deal with Avion Pharma,2014-08-14 08:00:00-04:00,LGND,neutral
759999.0,Marinus Pharma Announces Collaboration with Division of Ligand For Clinical Use of Captisol,2014-08-12 07:31:00-04:00,LGND,neutral
760000.0,"Stocks To Watch For August 12, 2014",2014-08-12 04:04:00-04:00,LGND,neutral
760001.0,"Ligand Pharma Reports $225M Offering of Convertible Senior Notes, $200M Buyback Plan",2014-08-11 16:03:00-04:00,LGND,neutral
760002.0,Exclusive: Emmanuel Lemelson Talks Ligand Pharmaceuticals,2014-08-07 13:57:00-04:00,LGND,positive
760003.0,Ligand Pharmaceuticals Reports Earnings; Lemelson Capital Adds To Short Position,2014-08-04 15:45:00-04:00,LGND,neutral
760004.0,Lemelson Capital Management Says Has Further Increased Short Position in Ligand Pharmaceuticals,2014-08-04 14:48:00-04:00,LGND,positive
760005.0,Ligand Pharmaceuticals Incorporated Sees Q3 EPS $0.26-0.29; Sees Sales $13.0M-14.0M vs $17.0M Est,2014-08-04 08:33:00-04:00,LGND,neutral
760006.0,Ligand Pharmaceuticals Incorporated Raises FY2014 EPS Guidance from $1.40-1.45 to $1.50-1.55 vs $1.44 Est; Sees Sales $64.0M-66.0M vs $63.0M Est,2014-08-04 08:32:00-04:00,LGND,neutral
760007.0,Ligand Pharmaceuticals Incorporated Reports Q2 EPS of $0.24 vs $0.14 Est; Revenue of $10.61M vs $9.67M Est,2014-08-04 08:32:00-04:00,LGND,neutral
760008.0,"Earnings Scheduled For August 4, 2014",2014-08-04 05:14:00-04:00,LGND,neutral
760009.0,"Option Alert: Sep $60 Call; 2,000 Contracts Traded vs 74 OI; Currently $50.20",2014-07-31 11:30:00-04:00,LGND,positive
760010.0,Ligand's SAGE Therapeutics Announces SAGE-547 Received Fast Track Designation to Treat Status Epilepticus,2014-07-22 13:15:00-04:00,LGND,positive
760011.0,"Empire Asset Management Initiates Coverage on Ligand Pharmaceuticals Incorporated at Sell, Announces $16.00 PT",2014-07-22 12:14:00-04:00,LGND,positive
760012.0,"Empire Asset Management Initiates Coverage on Ligand Pharmaceuticals Incorporated at Sell, Announces $16.00 PT",2014-07-22 09:32:00-04:00,LGND,positive
760013.0,Ligand Announces $10M Buyback,2014-07-17 08:03:00-04:00,LGND,neutral
760014.0,Ligand Pharmaceuticals Incorporated Raises Q2 Sales Guidance from $9.0M-9.50M to $10.60M,2014-07-17 08:02:00-04:00,LGND,neutral
760015.0,Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On Downbeat Results,2014-07-16 15:57:00-04:00,LGND,positive
760016.0,Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher,2014-07-16 13:36:00-04:00,LGND,positive
760017.0,Ligan Partner Announces Start of Phase 3 Eltrombopag,2014-06-25 08:31:00-04:00,LGND,neutral
760018.0,Benzinga's Volume Movers,2014-06-24 10:41:00-04:00,LGND,neutral
760019.0,TG Therapeutics Completes Licensing Agreement With Ligand Pharma to Develop Inhibitors of IRAK4,2014-06-24 08:10:00-04:00,LGND,positive
760020.0,Ligand Signs License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program,2014-06-24 05:49:00-04:00,LGND,positive
760021.0,Ligand to Present Positive Data from Phase 1 Study of Effect of SERN Lasofoxifene ,2014-06-23 08:03:00-04:00,LGND,positive
760022.0,Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial,2014-06-17 12:26:00-04:00,LGND,positive
760023.0,Shares of Ligand Pharma Tick Lower Following Word from Lemelson Capital Fund Has Initiated Short Position in Stock,2014-06-16 14:38:00-04:00,LGND,neutral
760024.0,Ligand Announces Successful Phase 1 Trial For LGN-6972,2014-06-16 08:04:00-04:00,LGND,positive
760025.0,"Ligand Announces Glaxo Has Presented Results from Phase 3 PETIT2 Study on Eltrombopag, Met Primary Endpoint",2014-06-13 07:31:00-04:00,LGND,neutral
760026.0,"Ligand Pharmaceuticals Licenses Five Programs to Viking Therapeutics, Extends $2.5M Loan Facility",2014-05-22 16:02:00-04:00,LGND,positive
760027.0,UPDATE: Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases,2014-05-14 08:35:00-04:00,LGND,positive
760028.0,"Ligand Enters into Research and License Agreement with Omthera Pharmaceuticals, a Wholly-owned Subsidiary of AstraZeneca -8-K",2014-05-14 06:58:00-04:00,LGND,positive
760029.0,UPDATE: Ligand Pharma Announces Milestone from Sage Therapeutics for SAGE-547,2014-05-12 08:05:00-04:00,LGND,neutral
760030.0,Ligand Pharma Announces Milestone from Sage Therapeutics for SAGE-547,2014-05-12 08:00:00-04:00,LGND,neutral
760031.0,Ligand Pharmaceuticals Incorporated Reports Q1 EPS of $0.35 vs $0.25 Est; Revenue of $16.0M vs $13.63M Est,2014-05-07 08:30:00-04:00,LGND,neutral
760032.0,Spectrum Pharmaceuticals' Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint ,2014-04-23 07:12:00-04:00,LGND,neutral
760033.0,"Brinson Patrick Initiates Coverage on Ligand Pharmaceuticals Incorporated at Outperform, Announces $98.00 PT",2014-03-24 10:03:00-04:00,LGND,neutral
760034.0,Ligand Pharma Announces $1M Milestone Payment Triggered Following FDA Approval of Merck's Noxafil,2014-03-17 08:20:00-04:00,LGND,positive
760035.0,UPDATE: Captisol Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV ,2014-03-10 10:14:00-04:00,LGND,positive
760036.0,UPDATE: MLV & Co Reiterates on Ligand Pharmaceuticals Following Strong 4Q Report,2014-02-13 08:08:00-05:00,LGND,negative
760037.0,"McNicoll Lewis Vlak Maintains Buy on Ligand Pharmaceuticals Incorporated, Raises PT to $96.00",2014-02-13 06:29:00-05:00,LGND,neutral
760038.0,Ligand Pharmaceuticals Incorporated Sees Q1 EPS $0.22-0.25,2014-02-11 08:40:00-05:00,LGND,neutral
760039.0,Ligand Pharmaceuticals Incorporated Reports Q4 EPS of $0.35 vs $0.19 Est; Revenue of $14.70M vs $14.25M Est,2014-02-11 08:40:00-05:00,LGND,neutral
760040.0,Ligand to Receive $1M Kyprolis Commercial Milestone Payment from Onyx Pharmaceuticals ,2014-02-10 16:17:00-05:00,LGND,neutral
760041.0,"Roth Says Use of New Promacta May Provide 'Meaningful' Royalties, EPS Growth to Ligand",2014-02-03 12:41:00-05:00,LGND,positive
760042.0,Ligand Partner GlaxoSmithKline Receives FDA Breakthrough Therapy Designation for Promacta/Revolade for Severe Aplastic Anemia,2014-02-03 07:30:00-05:00,LGND,negative
760043.0,UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals as Key Partnered Program Advances,2013-12-10 12:34:00-05:00,LGND,neutral
760044.0,Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at ASH,2013-12-09 05:57:00-05:00,LGND,positive
760045.0,Ligand Pharmaceuticals Sees FY 2013 Non-GAAP EPS from Continuing Operations per Diluted Share $0.86-$0.87 vs $0.77-$0.79 ,2013-12-04 06:03:00-05:00,LGND,positive
760046.0,Ligand Pharmaceuticals Sees Q4 EPS $0.31-$0.32 vs $0.22-$0.24; Q4 Revenue $14.0M-$14.5M vs $11.0M-$12.0M,2013-12-04 05:57:00-05:00,LGND,neutral
760047.0,Standard & Poors Announces Ligand Pharma Will Replace SHFL Entertainment in S&P SmallCap 600,2013-11-25 17:18:00-05:00,LGND,positive
760048.0,Ligand Pharmaceuticals Incorporated Sees FY2016 EPS Over $3.18; Sees Sales Over $106.0M,2013-11-14 16:16:00-05:00,LGND,neutral
760049.0,Ligand Pharmaceuticals Incorporated Sees FY2015 EPS Over $2.13; Sees Sales Over $81.0M,2013-11-14 16:15:00-05:00,LGND,neutral
760050.0,Ligand Pharmaceuticals Incorporated Sees FY2014 EPS $1.40-1.45; Sees Sales $62.0M-64.0M,2013-11-14 16:15:00-05:00,LGND,neutral
760051.0,Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes,2013-11-12 08:24:00-05:00,LGND,negative
760052.0,"Brean Capital Downgrades Ligand Pharmaceuticals Incorporated to Hold, Removes $45.00 PT",2013-10-31 09:05:00-04:00,LGND,neutral
760053.0,Ligand Pharmaceuticals Incorporated Reports Q3 EPS of $0.12 vs $0.07 Est; Revenue of $13.01M vs $10.82M Est,2013-10-30 08:33:00-04:00,LGND,neutral
760054.0,Ligand Highlights Pfizer's FDA Approval for DUAVEETM for Hot Flashes Related to Menopause,2013-10-03 17:02:00-04:00,LGND,positive
760055.0,Ligand Partner GSK Receives Marketing Authorization from EC for Additional Revolade Indication as Treatment for Chronic Hepatitis C-Associated Thrombocytopenia ,2013-09-24 07:06:00-04:00,LGND,neutral
760056.0,Ligand Enters Global License Agreement with CURx Pharmaceuticals for Captisol-Enabled Topiramate Injection ,2013-08-14 08:04:00-04:00,LGND,positive
760057.0,"Cantor Fitzgerald Downgrades Ligand Pharmaceuticals Incorporated to Sell, Raises PT to $37.00",2013-08-02 08:17:00-04:00,LGND,neutral
760058.0,"Bloomberg Reporting Ligand Pharma, The Medicines Co. Have Mutually Terminated License Deal with CyDex Unit",2013-08-01 11:08:00-04:00,LGND,neutral
760059.0,Ligand Pharmaceuticals Incorporated Reports Q2 EPS of $0.07 vs $0.06 Est; Revenue of $9.58M vs $9.30M Est,2013-08-01 08:31:00-04:00,LGND,neutral
760060.0,Ligand Announces GlaxoSmithKline Wins Positive CHMP Opinion for REVLOADE,2013-07-26 08:45:00-04:00,LGND,positive
760061.0,Ligand Receives FDA Orphan Designation for Captisol-Enabled Topiramate Injection ,2013-07-26 06:37:00-04:00,LGND,neutral
760062.0,Ligand Pharma Announces License Deal with Ethicor for Oral Lasofoxifene,2013-07-24 08:31:00-04:00,LGND,neutral
760063.0,Ligand Signs Global License Deal with Azure for Lasofoxifene,2013-07-22 08:32:00-04:00,LGND,neutral
760064.0,Benzinga's Volume Movers,2013-07-01 10:44:00-04:00,LGND,neutral
760065.0,Ligand Pharma Announces Preclinical Data for Glucagon Program,2013-06-24 08:34:00-04:00,LGND,neutral
760066.0,Afternoon Market Movers,2013-06-20 12:48:00-04:00,LGND,neutral
760067.0,Ligand Pharma Boosts Ownership Limit for BVF to 25% of Outstanding Shares,2013-06-20 08:32:00-04:00,LGND,positive
760068.0,Ligand Pharma Sees FY14 Adj. EPS Above $1.05 vs $0.95 Est.,2013-05-29 08:35:00-04:00,LGND,neutral
760069.0,Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV ,2013-05-14 08:33:00-04:00,LGND,neutral
760070.0,"Ligand Announces $5M Buyback, Q1 Earnings",2013-05-08 16:14:00-04:00,LGND,neutral
760071.0,Ligand Pharmaceuticals Incorporated Reports Q1 EPS of $0.07 vs $0.09 Est; Revenue of $11.70M vs $10.0M Est,2013-05-08 16:04:00-04:00,LGND,neutral
760072.0,Ligand Pharmaceuticals Incorporated Reports Q1 EPS of $0.06 vs $0.09 Est; Revenue of $11.65M vs $10.0M Est,2013-05-08 16:03:00-04:00,LGND,neutral
760073.0,Stocks Hitting 52-Week Highs,2013-04-22 10:34:00-04:00,LGND,neutral
760074.0,UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership,2013-03-18 08:30:00-04:00,LGND,neutral
760075.0,"Cantor Fitzgerald Maintains Hold on Ligand Pharmaceuticals Incorporated, Raises PT to $26.00",2013-03-18 07:17:00-04:00,LGND,neutral
760076.0,Ligand Pharmaceuticals Incorporated Raises FY2013 EPS Guidance from $0.35-0.39 to $0.47-0.51 vs $0.37 Est; Raises FY2013 Sales Guidance from $41.0M-44.0M to $43.0M-46.0M vs $43.20M Est,2013-03-14 07:27:00-04:00,LGND,neutral
760077.0,Ligand Pharmaceuticals Incorporated Sees Q1 EPS $0.10-0.13 vs $(0.01) Est; Sees Sales $10.0M-11.0M vs $8.04M Est,2013-03-14 07:26:00-04:00,LGND,neutral
760078.0,"Ligand,  Spectrum Pharmaceuticals in Global License Agreement",2013-03-14 07:02:00-04:00,LGND,positive
760079.0,Ligand Pharmaceuticals Incorporated Sees FY2013 EPS $0.35-0.39 vs $0.39 Est; Sees Sales $41.0M-44.0M vs $43.20M Est,2013-02-13 16:28:00-05:00,LGND,neutral
760080.0,Ligand Pharmaceuticals Incorporated Reports Q4 EPS of $0.13 vs $0.21 Est; Revenue of $13.64M vs $13.27M Est,2013-02-13 16:27:00-05:00,LGND,neutral
760081.0,Ligand Pharma Wins Equity Milestone Payment from Retrophin,2013-01-09 09:01:00-05:00,LGND,positive
760082.0,"UPDATE: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals to Hold, Lowers PT",2013-01-04 08:38:00-05:00,LGND,negative
760083.0,"Cantor Fitzgerald Downgrades Ligand Pharmaceuticals Incorporated to Hold, Lowers PT to $23.00",2013-01-04 06:57:00-05:00,LGND,negative
760084.0,"FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens",2012-12-13 17:05:00-05:00,LGND,positive
760085.0,Ligand Pharma Begins Pivotal Trial of Captisol-Enabled Propylene Glycol-Free Melphalan for Multiple Myeloma Patients,2012-12-10 16:09:00-05:00,LGND,neutral
760086.0,"UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Ligand Pharmaceuticals",2012-12-07 10:48:00-05:00,LGND,neutral
760087.0,"Cantor Fitzgerald Maintains Buy on Ligand Pharmaceuticals Incorporated, Raises PT to $28.00",2012-12-07 09:55:00-05:00,LGND,neutral
760088.0,UPDATE: Ligand Pharmaceuticals Incorporated Sees FY2012 EPS $(0.09)-(0.13),2012-12-04 08:44:00-05:00,LGND,neutral
760089.0,UPDATE: Ligand Pharmaceuticals Incorporated Sees Q4 EPS $0.14-0.18 vs $0.26 Est,2012-12-04 08:43:00-05:00,LGND,neutral
760090.0,Ligand Pharmaceuticals Incorporated Sees FY2013 EPS Above $0.35 vs $0.43 Est; Sees Sales $41.0M-44.0M vs $45.0M Est,2012-12-04 08:41:00-05:00,LGND,neutral
760091.0,"UPDATE: Ligand Sees FY14 Sales More Than $60M, EPS Above $1.05",2012-12-04 08:41:00-05:00,LGND,neutral
760092.0,Benzinga's Volume Movers,2012-11-19 10:46:00-05:00,LGND,neutral
760093.0,Ligand Pharma Resumes Up 8.5%,2012-11-19 09:45:00-05:00,LGND,neutral
760094.0,Ligand Pharma to Resume Trading at 9:45AM EST,2012-11-19 09:16:00-05:00,LGND,neutral
760095.0,"Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication",2012-11-19 09:11:00-05:00,LGND,positive
760096.0,Hearing Ligand Pharma's Promacta Has Been Approved for the Treatment of HepC Patients with Low Blood Platelet Counts,2012-11-19 09:06:00-05:00,LGND,positive
760097.0,Ligand Pharma Halted with News Pending,2012-11-19 08:56:00-05:00,LGND,neutral
760098.0,Ligand Pharma Announces Preclinical Data for LG-7501,2012-11-13 09:08:00-05:00,LGND,neutral
760099.0,Ligand Pharmaceuticals Reports Q3 EPS $-0.01 vs $-0.03 Est; Revenues $6.4M vs $6.08M Est,2012-11-05 16:16:00-05:00,LGND,neutral
760100.0,"UPDATE: Ligand Guides Q4 Revenue About $13M, Had Seen $11M vs $10.8M Est; Guides Q3 Revenue $6M, Had Seen $8M vs $8.4M Est",2012-10-22 08:32:00-04:00,LGND,neutral
760101.0,Ligand to Receive $2 Million Milestone Payment from Merck; Re-Affirms FY Forecast,2012-10-22 08:31:00-04:00,LGND,neutral
760102.0,Ligand Pharmaceuticals Reports Q2 EPS $-0.20 May Not Compare to $-0.02 Est; Revenues $5.7M vs $7.13M Est,2012-08-08 16:06:00-04:00,LGND,neutral
760103.0,Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection   ,2012-07-25 07:16:00-04:00,LGND,neutral
760104.0,UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals from $19 to $24,2012-07-23 09:41:00-04:00,LGND,neutral
760105.0,Ligand Pharmaceuticals Spiking Higher in Onyx Kyprolis Approval,2012-07-20 11:35:00-04:00,LGND,positive
760106.0,Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene,2012-07-19 09:03:00-04:00,LGND,positive
760107.0,"Ligand Pharmaceuticals Spikes Higher After-Hours on Positive FDA Panel Vote on Onyx Pharmaceuticals' Kyprolis, Ligand to Receive Royalties",2012-06-20 16:25:00-04:00,LGND,positive
760108.0,Ligand Pharmaceuticals Spikes to Highs of Day; Company will Receive Royalty on Onyx Pharmaceuticals' Kyprolis Sales,2012-06-20 15:35:00-04:00,LGND,neutral
760109.0,Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions   ,2012-06-11 08:03:00-04:00,LGND,positive
760110.0,"Cantor Fitzgerald Initiates Ligand Pharmaceuticals at Buy, $19 PT",2012-06-07 16:21:00-04:00,LGND,neutral
760111.0,Ligand Pharma Files $30M Share Shelf,2012-03-26 08:07:00-04:00,LGND,positive
760112.0,Ligand Licenses DARA Program to Retrophin; Potential For Over $75 Million In Milestone Payments to Ligand Plus Royalties   ,2012-02-21 08:06:00-05:00,LGND,neutral
760113.0,"MLV & Co Affirms Ligand Pharmaceuticals Buy, $30 PT ",2012-02-08 16:18:00-05:00,LGND,neutral
760114.0,"From Earlier: Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled, Propylene Glycol-Free Melphalan ",2012-02-02 07:24:00-05:00,LGND,positive
760115.0,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed,2011-12-21 08:03:00-05:00,LGND,positive
760116.0,Ligand Announces Positive Preclinical Data ,2011-12-12 16:30:00-05:00,LGND,positive
760117.0,"Griffin Securities Initiates Ligand Pharma at Buy, $18 PT",2011-11-22 10:31:00-05:00,LGND,positive
760118.0,Edison Investment Research Expects Growth for Ligand Pharmaceuticals ,2011-11-14 08:31:00-05:00,LGND,positive
760119.0,"McNicoll, Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals ",2011-11-11 09:22:00-05:00,LGND,neutral
760120.0,Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting   ,2011-11-07 09:02:00-05:00,LGND,positive
760121.0,McNicoll Lewis & Vlak Maintains Buy Rating and $30 PT on Ligand Pharmaceuticals ,2011-11-07 08:06:00-05:00,LGND,neutral
760122.0,Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?,2011-11-02 08:46:00-04:00,LGND,neutral
760123.0,Ligand Announces Successful Phase II Results for Captisol-Enabled Propylene Glycol-Free Melphalan,2011-11-02 08:07:00-04:00,LGND,positive
760124.0,Ligand Enters into Platform Captisol License Agreement with SAGE Therapeutics   ,2011-10-19 08:02:00-04:00,LGND,positive
760125.0,"McNicoll, Lewis & Vlak Reiterates Ligand Pharmaceuticals Buy, $30 Price Target",2011-10-10 15:15:00-04:00,LGND,neutral
760126.0,Ligand to Get $4M in Licensing Payments From China Pact,2011-10-10 09:08:00-04:00,LGND,neutral
760127.0,Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®   ,2011-10-10 08:02:00-04:00,LGND,positive
760128.0,Wednesday's Biotech Stocks Trading,2011-09-08 12:27:00-04:00,LGND,neutral
760129.0,Mad Money Lightning Round: Cramer Likes Ligand Pharmaceuticals,2011-09-08 03:58:00-04:00,LGND,negative
760130.0,"C.K. Cooper Reiterates Ligand Pharmaceuticals Buy, Raises PT",2011-07-26 14:53:00-04:00,LGND,neutral
760131.0,Ligand Enters into Captisol Commercial Supply Agreement with Merck   ,2011-06-20 08:03:00-04:00,LGND,positive
760132.0,8 Stocks With Significant Insider Buying,2011-06-10 12:07:00-04:00,LGND,positive
760133.0,"Ligand Presents Phase IIa Data on Captisol-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011   ",2011-06-06 08:14:00-04:00,LGND,neutral
760134.0,Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting   ,2011-06-06 08:08:00-04:00,LGND,neutral
760135.0,Ligand and Medicines Company Agree to Worldwide License for Proprietary Captisol®-Enabled Intravenous Formulation of Clopidogrel,2011-06-03 09:06:00-04:00,LGND,positive
760136.0,"Ligand Partner Prism Pharmaceuticals To Be Acquired By Baxter (LGND, BAX)",2011-04-20 08:01:00-04:00,LGND,neutral
760137.0,Ligand Names Matthew W. Foehr COO,2011-04-18 16:17:00-04:00,LGND,neutral
760138.0,"Benzinga's Volume Movers (ARGN, OSTK, MALL, LGND)",2011-02-28 10:42:00-05:00,LGND,neutral
760139.0,Ligand Acquires CyDex Pharmaceuticals for $35.5M,2011-01-26 16:22:00-05:00,LGND,neutral
760140.0,Ligand Forms Alliance with Chiva Pharmaceuticals   ,2011-01-06 08:12:00-05:00,LGND,neutral
760141.0,Ligand Earns $1 Million Upfront Payment from Pfizer,2010-12-22 08:09:00-05:00,LGND,neutral
760142.0,Ligand 1 for 6 Reverse Stock Split Effective Today ,2010-11-19 08:32:00-05:00,LGND,positive
760143.0,Ligand Announces 1-for-6 Reverse Stock Split,2010-11-09 16:07:00-05:00,LGND,neutral
760144.0,Ligand Awarded $2 Million from U.S. Government ,2010-11-02 08:08:00-04:00,LGND,positive
760145.0,Ligand Appoints Sunil Patel to Board of Directors,2010-10-08 08:10:00-04:00,LGND,neutral
760146.0,Ligand Enters into Agreement with Proximagen for CXCR4 Target,2010-09-17 08:12:00-04:00,LGND,positive
760147.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,LGND,positive
760148.0,Ligand  (LGND) Completes Neurogen  (NRGN) Acquisition,2009-12-24 06:08:00-05:00,LGND,neutral
760149.0,"Benzinga’s Top Pre- Market Gainers (TRBN, LGND, DYAX, VRGY, HIBB, NLST)",2009-11-20 09:30:00-05:00,LGND,positive
760150.0,Ligand (LGND) to Buy Metabasis (MBRX) for Cash of $3.2M and Contingent Value Rights,2009-10-27 07:44:00-04:00,LGND,positive
